Dupilumab efficacy in patients with type 2 asthma and early F level reductions
Pavord, Ian (University of Oxford)
Wechsler, Michael E (National Jewish Health)
Busse, William (University of Wisconsin School of Medicine and Public Health)
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Xia, Changming (Regeneron Pharmaceuticals Inc, Tarrytown)
Gall, Rebecca (Regeneron Pharmaceuticals Inc, Tarrytown)
Pandit-Abid, Nami (Sanofi, Morristown)
Jacob-Nara, Juby A (Sanofi, Morristown)
Radwan, Amr (Regeneron Pharmaceuticals Inc, Tarrytown)
Rowe, Paul J (Sanofi, Morristown)
Deniz, Yamo (Regeneron Pharmaceuticals Inc, Tarrytown)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2025
Resum:	The QUEST ( identifier ) and TRAVERSE () studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab, 300 mg, for an additional 96 weeks (TRAVERSE) in patients with uncontrolled, moderate-to-severe asthma. This analysis assessed dupilumab efficacy in patients from QUEST who enrolled in TRAVERSE and were stratified by a reduction in fractional exhaled nitric oxide (F) level by week 2 of QUEST. Patients with an F level of at least 25 ppb at parent study baseline (PSBL) were defined as those with or without a minimally important F level reduction/response (a ≥20% reduction in patients with an F level of ≥50 ppb and a reduction of >10 ppb in those with an F level of <50 ppb at PSBL) by week 2 of QUEST. We assessed annualized severe exacerbation rates (AERs) and changes from PSBL in prebronchodilator FEV value, 5-item Asthma Control Questionnaire score, and Asthma Quality of Life Questionnaire score. During QUEST, dupilumab (compared with placebo) reduced AER by 58% to 59% across F response subgroups (unadjusted AER = 0. 392-0. 523 for dupilumab vs 1. 052-1. 280 for placebo) and improved prebronchodilator FEV value regardless of F response. These improvements were sustained during TRAVERSE, with a slightly greater magnitude in F responders. Dupilumab also improved 5-item Asthma Control Questionnaire and Asthma Quality of Life Questionnaire scores independently of F responses. Dupilumab sustained efficacy for up to 3 years in patients with and without a minimally important early reduction in F level. Greater improvements were seen in patients with an early reduction in F level, but patients without such a reduction also showed favorable outcomes during their treatment with dupilumab.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Dupilumab ; Asthma ; Feno ; Asthma exacerbation ; Lung function ; Asthma control ; Asthma-related quality of life ; Early response
Publicat a:	Journal of Allergy and Clinical Immunology: Global, Vol. 4, Num. 3 (April 2025) , ISSN 2772-8293

DOI: 10.1016/j.jacig.2025.100474
PMID: 40458676

8 p, 337.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d’Investigació i Innovació Parc Taulí (I3PT)
Articles > Articles de recerca
Articles > Articles publicats